Åpnes i et worddokument med direkte linker til relevante studier.
Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer. NBCG16, PI: Jon Amund Kyte.
Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting. PI: Olav Engebråten.
ICON CA209-9FN: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with luminal B breast cancer. PI: Jon Amund Kyte.
En kvalitetssikringsstudie (etter Targit studien). PI: Steinar Lundgren.
Breast conserving surgery (BCT) after neoadjuvant therapy for large primary breast cancer (T2-T3) with infavourable tumor-to-breast size ratio(NEO‐BCT‐2). Kun aktuell ved inklusjon i I-BCT studien. PI: Helle Skjerven.
Presurgical treatment with letrozole and exemestane in postmenopausal patients with ER-positive, locally advanced breast cancer: an intra-patient, cross-over trial. PI: Jürgen Geisler.
PErsonalized TREatment of high-risk MAmmary Cancer – the PETREMAC Trial. Positive Trial. NBCG15, PI: Hans Petter Eikesdal.
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer. PI: Anna Sætersdal.
Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide, PI: Hans Petter Eikesdal.
Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost. PI: Ingvil Mjaaland.